{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-033752","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2022-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.495759+00:00","generated_at":"2026-06-27T09:13:02.120255+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Director Sara Brownstein resigns from Aeglea board citing disagreement over financing plans","bullets":["Sara Brownstein resigned as Class I director effective February 9, 2022.","Resignation attributed to disagreement regarding the Company's financing plans.","No successor or interim director announced at this time."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-033752","json":"https://secwatch.observer/filing/0001193125-22-033752.json","markdown":"https://secwatch.observer/filing/0001193125-22-033752.md","text":"https://secwatch.observer/filing/0001193125-22-033752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522033752/0001193125-22-033752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522033752/d304706d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T09:13:02.120255+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"691d0e8083","claim":"Sara Brownstein resigned as Class I Director at Spyre Therapeutics, Inc..","evidence_excerpt":"On February 9, 2022, Sara Brownstein advised the Board of Directors (the “Board”) of Aeglea BioTherapeutics, Inc. (the “Company”) that she would resign as a Class I director of the Board, effective on February 9, 2022. The Company believes Ms. Brownstein’s resignation was due to disagreement regarding the Company’s financing plans.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636282/000119312522033752/0001193125-22-033752-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}